| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | NOT_YET_RECRUITING | PHASE3 | 2025-10-31 | 2032-01 | 2028-12 |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2024-12-16 | 2027-08-30 | 2027-05-30 |
| NCT06016738 | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | RECRUITING | PHASE3 | 2023-11-16 | 2027-09-30 | 2026-06-30 |
| NCT05508906 | Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, or Everolimus in ER+, HER2- Breast Cancer | ACTIVE_NOT_RECRUITING | PHASE1 | 2022-08-31 | 2026-09-09 | 2026-08-09 |
| NCT05266105 | A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients | ACTIVE_NOT_RECRUITING | PHASE1 | 2021-12-10 | 2025-07 | 2025-01 |
| NCT04505826 | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | COMPLETED | PHASE1, PHASE2 | 2020-08-13 | 2024-07-30 | 2024-07-30 |